ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
ACCESS: Study of Donor Blood Stem Cell Transplant in Patients with Multiple Myeloma, Leukemia, or Lymphoma
Sponsor: NMDP
Enrolling: Male and Female Patients
IRB Number: AAAT7521
U.S. Govt. ID: NCT04904588
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see how well an allogenic transplant works in adults with an MMUD using stem cells from a donor's blood (instead of using the donor's bone marrow). An allogeneic stem cell transplant is a standard treatment for blood cancers. An allogeneic transplant replaces your abnormal (or diseased) blood cells with healthy blood-making cells from a donor. We're doing this study to see how well transplant works in adults with an MMUD using stem cells from a donor's blood. This study treatment does not include any investigational drugs.
This study is closed
Investigator
Ran Reshef, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with multiple myeloma, leukemia, or lymphoma? Yes No
Is your liver functional? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162